Cargando…

Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain

OBJECTIVE: To explore adherence/persistence with generic gabapentin/venlafaxine versus brand-name gabapentin/venlafaxine (Neurontin(®)/Vandral(®)) in peripheral neuropathic pain (pNP) or generalized anxiety disorder (GAD), respectively, and whether it is translated into different costs and patient o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sicras-Mainar, Antoni, Rejas-Gutiérrez, Javier, Navarro-Artieda, Ruth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461091/ https://www.ncbi.nlm.nih.gov/pubmed/26082655 http://dx.doi.org/10.2147/CEOR.S85756

Ejemplares similares

Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity
por: Sicras‐Mainar, Antoni, et al.
Publicado: (2016)

Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis
por: Sicras-Mainar, A., et al.
Publicado: (2018)

Physicians’ and patients’ opinions on the use of generic drugs
por: Sicras-Mainar, Antoni, et al.
Publicado: (2012)

Influence of the CYP2D6 Isoenzyme in Patients Treated with Venlafaxine for Major Depressive Disorder: Clinical and Economic Consequences
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Relationship between obesity and antipsychotic drug use in the adult population: A longitudinal, retrospective claim database study in Primary Care settings
por: Sicras-Mainar, Antoni, et al.
Publicado: (2008)

Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain
por: Rejas-Gutierrez, Javier, et al.
Publicado: (2021)

Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2007)

Severe Atopic Dermatitis In Spain: A Real-Life Observational Study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2019)

Impact on healthcare resource utilization of multiple sclerosis in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2017)

Comorbidity and metabolic syndrome in patients with multiple sclerosis from Asturias and Catalonia, Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2017)

Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2013)

Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2022)

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients
por: Sicras-Mainar, Antoni, et al.
Publicado: (2015)

Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J 2015;39:74-81)
por: Sicras-Mainar, Antoni, et al.
Publicado: (2015)

Use of antidepressants in the treatment of major depressive disorder in primary care during a period of economic crisis
por: Sicras-Mainar, Antoni, et al.
Publicado: (2015)

Healthcare use and costs associated with obesity in Badalona, Spain: a study protocol
por: Sicras-Mainar, Antonio, et al.
Publicado: (2012)

Brand Name Versus Generic?
por: Aungaroon, Gewalin
Publicado: (2023)

Health outcomes and costs in patients with osteoarthritis and chronic pain treated with opioids in Spain: the OPIOIDS real-world study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2020)

Adaptive capacity of the Adjusted Clinical Groups Case-Mix System to the cost of primary healthcare in Catalonia (Spain): a observational study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2012)

Retrospective epidemiological study for the characterization of community- acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain)
por: Sicras-Mainar, Antoni, et al.
Publicado: (2012)

Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia
por: Sicras-Mainar, Antoni, et al.
Publicado: (2017)

Treatment profiles and costs of patients with chronic pain in the population setting
por: Mainar, Antoni Sicras, et al.
Publicado: (2012)

Cost and clinical consequences of smoking cessation in outpatients after cardiovascular disease: a retrospective cohort study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2013)

Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care
por: Sicras-Mainar, Antoni, et al.
Publicado: (2012)

Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Disease Burden and Costs in Moderate-to-Severe Chronic Osteoarthritis Pain Refractory to Standard of Care: Ancillary Analysis of the OPIOIDS Real-World Study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2021)

Clinical validity of a population database definition of remission in patients with major depression
por: Sicras-Mainar, Antoni, et al.
Publicado: (2010)

The concept of: Generic drugs and patented drugs vs. brand name drugs and non-proprietary (generic) name drugs
por: Thakkar, Karan B., et al.
Publicado: (2013)

Generic versus brand-name drugs used in cardiovascular diseases
por: Manzoli, Lamberto, et al.
Publicado: (2015)

Generics versus brand-named drugs for glaucoma: the debate continues
por: Bhartiya, Shibal, et al.
Publicado: (2020)

Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study
por: Sicras-Mainar, Antoni, et al.
Publicado: (2009)

Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease
por: Sicras Mainar, Antoni, et al.
Publicado: (2019)

North American cost analysis of brand name versus generic drugs for the treatment of glaucoma
por: Malvankar-Mehta, Monali S, et al.
Publicado: (2019)

Safety of switching from brand-name to generic levetiracetam in patients with epilepsy
por: Bosak, Magdalena, et al.
Publicado: (2017)

Elemental impurities analysis in name-brand and generic omeprazole drug samples
por: Pinheiro, Fernanda C., et al.
Publicado: (2020)

Comparison of Pharmaceutical Characteristics between Brand-Name Meropenem and Its Generics
por: Yang, Ping, et al.
Publicado: (2021)

What’s in a Name? Use of Brand versus Generic Drug Names in United States Outpatient Practice
por: Steinman, Michael A., et al.
Publicado: (2007)

The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
por: Sarpatwari, Ameet, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_llq5ac2t01rb40hs73g93tv8th